AstraZeneca Diabetes Combo Needs More Clinical Data, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Even though both components are already marketed, firm might have to do another study for fixed-dose combination of DPP-4 inhibitor saxagliptin and SGLT2 inhibitor dapagliflozin.